(Reuters) -Healthcare firm Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its initial public offering in the United States. The Mountain View, California-based company ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Back in May, Bain and Botanic spent $26 million to acquire the property from Fujifilm Recording Media. The 15-acre site will ...

Legendary 'is definitely in the ears of the beholder. We look for artists that have a true fan base,' Bain Capital's Angelo ...

Bain Capital LLC is a Boston-based private investment firm managing around $185 billion in assets across 24 offices worldwide. With over 1,750 employees, it invests across sectors such as credit ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...